Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD

The intravenous induction or loading dose in children is commonly prescribed per kilogram. That dose recognizes the linear relationship between volume of distribution and total body weight. Total body weight comprises both fat and fat-free mass. Fat mass influences the volume of distribution and the use of total body weight fails to recognize the impact of fat mass on pharmacokinetics in children. Size metrics alternative to total body mass (e.g., fat-free and normal fat mass, ideal body weight and lean body weight) have been proposed to scale pharmacokinetic parameters (clearance, volume of distribution) for size. Clearance is the key parameter used to calculate infusion rates or maintenance dosing at steady state. Dosing schedules recognize the curvilinear relationship, described using allometric theory, between clearance and size. Fat mass also has an indirect influence on clearance through both metabolic and renal function that is independent of its effects due to increased body mass. Fat-free mass, lean body mass and ideal body mass are not drug specific and fail to recognize the variable impact of fat mass contributing to body composition in children, both lean and obese. Normal fat mass, used in conjunction with allometry, may prove a useful size metric but computation by clinicians for the individual child is not facile. Dosing is further complicated by the need for multicompartment models to describe intravenous drug pharmacokinetics and the concentration effect relationship, both beneficial and adverse, is often poorly understood. Obesity is also associated with other morbidity that may also influence pharmacokinetics. Dose is best determined using pharmacokinetic–pharmacodynamic (PKPD) models that account for these varied factors. These models, along with covariates (age, weight, body composition), can be incorporated into programmable target-controlled infusion pumps. The use of target-controlled infusion pumps, assuming practitioners have a sound understanding of the PKPD within programs, provide the best available guide to intravenous dose in obese children.

[1]  P. Ramnarayan,et al.  Optimising intravenous salbutamol in children: a phase 2 study , 2022, Archives of Disease in Childhood.

[2]  V. Conti,et al.  Drug dosing in children with obesity: a narrative updated review , 2022, Italian Journal of Pediatrics.

[3]  D. Greenblatt,et al.  Drug Disposition in Subjects With Obesity: The Research Work of Darrell R. Abernethy , 2022, Journal of clinical pharmacology.

[4]  B. Anderson,et al.  Pharmacokinetic Pharmacodynamic Modelling Contributions to Improve Paediatric Anaesthesia Practice , 2022, Journal of clinical medicine.

[5]  B. Anderson,et al.  Population Pharmacokinetic Modelling of Acetaminophen and Ibuprofen: the Influence of Body Composition, Formulation and Feeding in Healthy Adult Volunteers , 2022, European Journal of Drug Metabolism and Pharmacokinetics.

[6]  N. Holford,et al.  Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates , 2021, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  J. Hannam,et al.  Population pharmacokinetics of oxycodone: Premature neonates to adults , 2021, Paediatric anaesthesia.

[8]  B. Anderson,et al.  Estimation of the Loading Dose for Target-Controlled Infusion of Dexmedetomidine. Reply to Eleveld et al. Comment on “Morse et al. A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. J. Clin. Med. 2020, 9, 3480” , 2021, Journal of Clinical Medicine.

[9]  R. ter Heine,et al.  Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies , 2020, European Journal of Clinical Pharmacology.

[10]  B. Anderson,et al.  A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults , 2020, Journal of clinical medicine.

[11]  N. Holford,et al.  TDM is dead. Long live TCI! , 2020, British journal of clinical pharmacology.

[12]  J. Sear,et al.  Pharmacokinetic and Pharmacodynamic Analysis of Alfaxalone Administered as a Bolus Intravenous Injection of Phaxan in a Phase 1 Randomized Trial , 2020, Anesthesia and analgesia.

[13]  J. Clarke,et al.  Ideal body weight in the precision era: recommendations for prescribing in obesity require thought for computer-assisted methods , 2019, Archives of Disease in Childhood.

[14]  J. Hannam,et al.  A manual propofol infusion regimen for neonates and infants , 2019, Paediatric anaesthesia.

[15]  J. Standing,et al.  Optimizing clonidine dosage for sedation in mechanically ventilated children: A pharmacokinetic simulation study , 2019, Paediatric anaesthesia.

[16]  A. Darzi,et al.  Assessing the Agreement of 5 Ideal Body Weight Calculations for Selecting Medication Dosages for Children With Obesity. , 2019, JAMA pediatrics.

[17]  Ricardo Fuentes,et al.  Propofol pharmacokinetic and pharmacodynamic profile and its electroencephalographic interaction with remifentanil in children , 2018, Paediatric anaesthesia.

[18]  B. Anderson,et al.  Effect-Site Target-Controlled Infusion in the Obese: Model Derivation and Performance Assessment , 2018, Anesthesia and analgesia.

[19]  J. Chávez-Pacheco,et al.  Population Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Children Undergoing Ambulatory Surgery , 2018, Anesthesia and analgesia.

[20]  M. Struys,et al.  Pharmacokinetic–pharmacodynamic model for propofol for broad application in anaesthesia and sedation , 2018, British journal of anaesthesia.

[21]  A. S. Leung,et al.  Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine , 2018, British journal of anaesthesia.

[22]  Bruno Reichart,et al.  Does size matter? , 2018, Xenotransplantation.

[23]  Stephen B. Duffull,et al.  A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass , 2018, Clinical Pharmacokinetics.

[24]  N. Holford,et al.  What is the best size predictor for dose in the obese child? , 2017, Paediatric anaesthesia.

[25]  M. Struys,et al.  Dexmedetomidine pharmacokinetic–pharmacodynamic modelling in healthy volunteers: 1. Influence of arousal on bispectral index and sedation , 2017, British journal of anaesthesia.

[26]  M. Struys,et al.  An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics , 2017, Anesthesiology.

[27]  N. Holford,et al.  Allometric size: The scientific theory and extension to normal fat mass , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  Nick Holford,et al.  Theory‐based pharmacokinetics and pharmacodynamics of S‐ and R‐warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients , 2017, British journal of clinical pharmacology.

[29]  K. Matson,et al.  Medication Dosage in Overweight and Obese Children. , 2017, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[30]  N. Holford,et al.  Getting the dose right for obese children , 2016, Archives of Disease in Childhood.

[31]  H. Collier,et al.  Prescribing in obese children: how good are paediatricians? , 2016, Archives of Disease in Childhood.

[32]  N. Holford,et al.  Salbutamol has rapid onset pharmacodynamics as a bronchodilator , 2016, Acta Anaesthesiologica Scandinavica.

[33]  Stephen Duffull,et al.  Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients. , 2016, British journal of clinical pharmacology.

[34]  J. Frazier,et al.  Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics , 2016, Clinical Pharmacokinetics.

[35]  N. Holford,et al.  Dexmedetomidine pharmacokinetics in the obese , 2015, European Journal of Clinical Pharmacology.

[36]  T. Inge,et al.  Population pharmacokinetic–pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents , 2015, Paediatric anaesthesia.

[37]  J. Berkenbosch,et al.  The impact of obesity on pediatric procedural sedation‐related outcomes: results from the Pediatric Sedation Research Consortium , 2015, Paediatric anaesthesia.

[38]  Hesham S. Al-Sallami,et al.  Prediction of Fat-Free Mass in Children , 2015, Clinical Pharmacokinetics.

[39]  M. Struys,et al.  Propofol Breath Monitoring as a Potential Tool to Improve the Prediction of Intraoperative Plasma Concentrations , 2015, Clinical Pharmacokinetics.

[40]  J. Jankiewicz-Wika,et al.  Reduced plasma level of diazepam-binding inhibitor (DBI) in patients with morbid obesity , 2015, Endocrine.

[41]  M. Görges,et al.  Identifying a rapid bolus dose of dexmedetomidine (ED50) with acceptable hemodynamic outcomes in children , 2014, Paediatric anaesthesia.

[42]  Michel M. R. F. Struys,et al.  A General Purpose Pharmacokinetic Model for Propofol , 2014, Anesthesia and analgesia.

[43]  J. Barrett,et al.  Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization , 2013, Clinical Cancer Research.

[44]  A. Åsberg,et al.  Importance of hematocrit for a tacrolimus target concentration strategy , 2013, European Journal of Clinical Pharmacology.

[45]  Nick Holford,et al.  A pharmacokinetic standard for babies and adults. , 2013, Journal of pharmaceutical sciences.

[46]  N. Holford,et al.  Understanding dosing: children are small adults, neonates are immature children , 2013, Archives of Disease in Childhood.

[47]  T. Merriman,et al.  The population pharmacokinetics of allopurinol and oxypurinol in patients with gout , 2013, European Journal of Clinical Pharmacology.

[48]  T. Inge,et al.  Propofol clearance in morbidly obese children and adolescents: influence of age and body size. , 2012, Clinical pharmacokinetics.

[49]  B. Anderson My child is unique; the pharmacokinetics are universal , 2012, Paediatric anaesthesia.

[50]  J. Beijnen,et al.  Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis , 2012, Antimicrobial Agents and Chemotherapy.

[51]  M. Jamei,et al.  Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients , 2011, Clinical pharmacokinetics.

[52]  M. Struys,et al.  Obesity and Allometric Scaling of Pharmacokinetics , 2011, Clinical Pharmacokinetics.

[53]  J. Brodsky,et al.  Lean Body Weight Scalar for the Anesthetic Induction Dose of Propofol in Morbidly Obese Subjects , 2011, Anesthesia and analgesia.

[54]  T. Lauritsen,et al.  Anesthetizing the obese child , 2011, Paediatric anaesthesia.

[55]  H. Lemmens,et al.  Dose adjustment of anaesthetics in the morbidly obese. , 2010, British journal of anaesthesia.

[56]  M. Struys,et al.  Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. , 2010, British journal of anaesthesia.

[57]  H. Lemmens Perioperative pharmacology in morbid obesity , 2010, Current opinion in anaesthesiology.

[58]  H. Mulla,et al.  Dosing dilemmas in obese children , 2010, Archives of Disease in Childhood: Education & Practice Edition.

[59]  A. Dahan,et al.  Propofol Reduces the Distribution and Clearance of Midazolam , 2010, Anesthesia and analgesia.

[60]  B. Anderson,et al.  Are there still limitations for the use of target-controlled infusion in children? , 2010, Current opinion in anaesthesiology.

[61]  G. Warman,et al.  Dexmedetomidine hemodynamics in children after cardiac surgery , 2010, Paediatric anaesthesia.

[62]  M. H. Ensom,et al.  Pharmacokinetics and drug dosing in obese children. , 2010, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[63]  N Holford,et al.  Dosing in Children , 2010, Clinical pharmacology and therapeutics.

[64]  B. Anderson Pediatric models for adult target‐controlled infusion pumps , 2010, Paediatric anaesthesia.

[65]  J. Standing,et al.  Pharmacokinetic–pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty , 2010, Paediatric anaesthesia.

[66]  N. Holford,et al.  Leaving no stone unturned, or extracting blood from stone? , 2010, Paediatric anaesthesia.

[67]  L. Rasmussen,et al.  Should Dosing of Rocuronium in Obese Patients Be Based on Ideal or Corrected Body Weight? , 2009, Anesthesia and analgesia.

[68]  A. Dahan,et al.  Mixed-Effects Modeling of the Influence of Midazolam on Propofol Pharmacokinetics , 2009, Anesthesia and analgesia.

[69]  M. Coulthard,et al.  Human renal function maturation: a quantitative description using weight and postmenstrual age , 2009, Pediatric Nephrology.

[70]  N. Holford,et al.  Mechanistic basis of using body size and maturation to predict clearance in humans. , 2009, Drug metabolism and pharmacokinetics.

[71]  L. Colla,et al.  Pharmacokinetic Model-Driven Remifentanil Administration in the Morbidly Obese , 2009, Clinical pharmacokinetics.

[72]  B. Goh,et al.  Does saturable formation of gemcitabine triphosphate occur in patients? , 2008, Cancer Chemotherapy and Pharmacology.

[73]  N. Holford,et al.  Mechanism-based concepts of size and maturity in pharmacokinetics. , 2008, Annual review of pharmacology and toxicology.

[74]  S. Duffull,et al.  Dosing in Obesity: A Simple Solution to a Big Problem , 2007, Clinical pharmacology and therapeutics.

[75]  T. Stephenson How children's responses to drugs differ from adults. , 2005, British journal of clinical pharmacology.

[76]  A. Casati,et al.  Anesthesia in the obese patient: pharmacokinetic considerations. , 2005, Journal of clinical anesthesia.

[77]  Stephen B. Duffull,et al.  Quantification of Lean Bodyweight , 2005, Clinical pharmacokinetics.

[78]  T. Pellis,et al.  The Effects of Cisatracurium on Morbidly Obese Women , 2004, Anesthesia and analgesia.

[79]  T. Pellis,et al.  The Pharmacodynamic Effects of Rocuronium When Dosed According to Real Body Weight or Ideal Body Weight in Morbidly Obese Patients , 2004, Anesthesia and analgesia.

[80]  S. Duffull,et al.  What is the best size descriptor to use for pharmacokinetic studies in the obese? , 2004, British journal of clinical pharmacology.

[81]  N. Holford,et al.  Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. , 2004, British journal of clinical pharmacology.

[82]  C. Kirkpatrick,et al.  A Standard Weight Descriptor for Dose Adjustment in the Obese Patient , 2004, Clinical pharmacokinetics.

[83]  L. Brennan,et al.  Childhood obesity: a challenge for the anaesthetist? , 2002, Paediatric anaesthesia.

[84]  G. Meakin,et al.  Scaling for size: some implications for paediatric anaesthesia dosing , 2002, Paediatric anaesthesia.

[85]  N. Holford,et al.  Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy , 2001, European Journal of Clinical Pharmacology.

[86]  R. Brolin,et al.  Efficacy and Safety of Patient-Controlled Analgesia for Morbidly Obese Patients Following Gastric Bypass Surgery , 2000, Obesity surgery.

[87]  J Schüttler,et al.  Population Pharmacokinetics of Propofol: A Multicenter Study , 2000, Anesthesiology.

[88]  S L Shafer,et al.  The influence of age on propofol pharmacodynamics. , 1999, Anesthesiology.

[89]  E Olofsen,et al.  The dynamic relationship between end-tidal sevoflurane and isoflurane concentrations and bispectral index and spectral edge frequency of the electroencephalogram. , 1999, Anesthesiology.

[90]  T. Short,et al.  The use of propofol infusions in paediatric anaesthesia: a practical guide , 1999, Paediatric anaesthesia.

[91]  T. Egan,et al.  Remifentanil Pharmacokinetics in Obese versus Lean Patients , 1998, Anesthesiology.

[92]  D. R. Wada,et al.  Determination of the Distribution Volume that can be Used to Calculate the Intravenous Loading Dose , 1998, Clinical pharmacokinetics.

[93]  N. Holford,et al.  Size, Myths and the Clinical Pharmacokinetics of Analgesia in Paediatric Patients , 1997, Clinical pharmacokinetics.

[94]  James H. Brown,et al.  A General Model for the Origin of Allometric Scaling Laws in Biology , 1997, Science.

[95]  Nicholas H. G. Holford,et al.  A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.

[96]  J. Whitwam,et al.  Flumazenil and midazolam in anaesthesia , 1995, Acta anaesthesiologica Scandinavica. Supplementum.

[97]  N H Holford,et al.  The Target Concentration Approach to Clinical Drug Development , 1995, Clinical pharmacokinetics.

[98]  D. Morgan,et al.  Lean Body Mass as a Predictor of Drug Dosage , 1994, Clinical pharmacokinetics.

[99]  S. Gatt,et al.  Epidural Catheters for Obstetrics: Terminal Hole or Lateral Eyes? , 1994, Regional Anesthesia & Pain Medicine.

[100]  R. Farinotti,et al.  Propofol Infusion for Maintenance of Anesthesia in Morbidly Obese Patients Receiving Nitrous Oxide A Clinical and Pharmacokinetic Study , 1993, Anesthesiology.

[101]  R. Matteo,et al.  Pharmacokinetics and Pharmacodynamics of Vecuronium in the Obese Surgical Patient , 1992, Anesthesia and analgesia.

[102]  D. Greenblatt,et al.  Prolonged Accumulation of Diazepam in Obesity , 1983, Journal of clinical pharmacology.

[103]  G. Forbes,et al.  Lean body mass in obesity. , 1983, International journal of obesity.

[104]  D. Greenblatt,et al.  Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). , 1982, Journal of pharmaceutical sciences.

[105]  D. Greenblatt,et al.  Digoxin disposition in obesity: clinical pharmacokinetic investigation. , 1981, American heart journal.

[106]  T. Lohman Skinfolds and body density and their relation to body fatness: a review. , 1981, Human biology.

[107]  U. Klotz,et al.  Pathophysiological and Disease-Induced Changes in Drug Distribution Volume: Pharmacokinetic Implications , 1976, Clinical pharmacokinetics.

[108]  B. Groves,et al.  Digoxin Metabolism in Obesity , 1971, Circulation.

[109]  B. Friis‐Hansen Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth. , 1971, Pediatrics.

[110]  A. Keys,et al.  Body fat in adult man. , 1953, Physiological reviews.

[111]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .